Nucl Med Mol Imaging.
2024 Aug;58(4):160-176. 10.1007/s13139-023-00831-4.
The development status of PET radiotracers for evaluating neuroinflammation
- Affiliations
-
- 1Division of Applied RI, Korea Institute of Radiological & Medical Sciences, 75 Nowon‑ro, Nowon‑gu, Seoul 01812, Korea
- 2Radiological and Medico‑Oncological Sciences, University of Science and Technology (UST), Seoul, Korea
- 3Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2558879
- DOI: http://doi.org/10.1007/s13139-023-00831-4
Abstract
- Neuroinflammation is associated with the pathophysiologies of neurodegenerative and psychiatric disorders. Evaluating neuroinflammation using positron emission tomography (PET) plays an important role in the early diagnosis and determination of proper treatment of brain diseases. To quantify neuroinflammatory responses in vivo, many PET tracers have been developed using translocator proteins, imidazole-2 binding site, cyclooxygenase, monoamine oxidase-B, adenosine, cannabinoid, purinergic P2X7, and CSF-1 receptors as biomarkers. In this review, we introduce the latest developments in PET tracers that can image neuroinflammation, focusing on clinical trials, and further consider their current implications.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases
- Radiotracers for Functional Neuroimaging
- Technetium 99m PSMA Superscan Mimicking a Bone Scan Gone Wrong
- Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma
- Amyloid PET Quantification Via End-to-End Training of a Deep Learning
